Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, Atallah E. Murthy GSG, et al. Among authors: abedin s. Haematologica. 2024 Apr 4. doi: 10.3324/haematol.2024.285014. Online ahead of print. Haematologica. 2024. PMID: 38572562 Free article.
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.
Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS. Mushtaq MU, et al. Among authors: abedin s. Leuk Lymphoma. 2021 Jan;62(1):158-166. doi: 10.1080/10428194.2020.1821009. Epub 2020 Sep 19. Leuk Lymphoma. 2021. PMID: 32951486
Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.
Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, Atallah EL, Abedin SM. Taylor S, et al. Among authors: abedin sm. Leuk Res. 2023 Sep;132:107348. doi: 10.1016/j.leukres.2023.107348. Epub 2023 Jun 28. Leuk Res. 2023. PMID: 37423073 No abstract available.
Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Abedin S, et al. Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694. doi: 10.1016/j.bbmt.2019.04.003. Epub 2019 Apr 6. Biol Blood Marrow Transplant. 2019. PMID: 30965140 Free article. Clinical Trial.
Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L. George G, et al. Among authors: abedin s. Leuk Res. 2020 Jul;94:106368. doi: 10.1016/j.leukres.2020.106368. Epub 2020 May 11. Leuk Res. 2020. PMID: 32442786 Clinical Trial. No abstract available.
144 results